Loading clinical trials...
Loading clinical trials...
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Conditions
Interventions
Bococizumab (PF-04950615;RN316)
Placebo
Locations
103
United States
Achieve Clinical Research, LLC
Birmingham, Alabama, United States
Cardiovascular Associates of the Southeast, LLC
Birmingham, Alabama, United States
Southwest Heart Group
Tucson, Arizona, United States
ARA-Arizona Research Associates
Tucson, Arizona, United States
Diagnamics, Inc.
Encinitas, California, United States
Encompass Clinical Research North Coast
Encinitas, California, United States
Start Date
October 1, 2013
Primary Completion Date
April 1, 2016
Completion Date
April 1, 2016
Last Updated
May 17, 2017
NCT06062394
NCT07230730
NCT07334834
NCT07311941
NCT06903897
NCT06055036
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions